Reto Stump

Reto Stump

Auto-generated profile, based on publicly available information

Reto Stump

Department of Cardiology, University Hospital Basel, University of Basel , Petersgraben 4, Basel 4031

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Hearing Research
Verified
Journal Article
Open access
RSReto Stump
Reto Stump
IDIvo Dobrev
Ivo Dobrev
NKNiklaus Krayenbühl
Niklaus Krayenbühl
RPRudolf Probst
Rudolf Probst
CRChristof Roosli
Christof Roosli
Bone conduction (BC) is an alternative to air conduction (AC) for stimulation of the inner ear. Stimulation for BC can occur directly on the skull bone, on the skin covering the skull bone, or on soft tissue (i.e., eye, dura). All of these stimuli can elicit otoacoustic emissions (OAE). This study aims to compare OAEs generated by different combinations of stimuli in live humans, including direct stimulation of the intracranial contents via the dura, measured intraoperatively. Measurements were performed in five normal-hearing ears of subjects undergoing a neurosurgical intervention with craniotomy in general anesthesia. Distortion product OAEs (DPOAEs) were measured for f2 at 0.7, 1, 2, 3, 4, and 6 kHz with a constant ratio of the primary frequencies (f2/f1) of 1.22. Sound pressure L1 was held constant at 65 dB SPL, while L2 was decreased in 10 dB steps from 70 to 30 dB SPL. A DPOAE was considered significant when its level was ≥6 dB above the noise floor. Emissions were generated sequentially with different modes of stimulation: 1) pre-operatively in the awake subject by two air-conducted tones (AC-AC); 2) within the same session preoperatively by one air- and one bone-conducted tone on the skin-covered temporal bone as in audiometry (AC-BC); 3) intra-operatively by one air-conducted tone and one bone-vibrator tone applied directly on the dura (AC-DC). A modified bone vibrator (Bonebridge; MED-EL, Innsbruck, Austria) was used for BC stimulation on the dura or skin-covered mastoid. Its equivalent perceived SPL was calibrated preoperatively for each individual by psychoacoustically comparing the level of a BC tone presented to the temporal region to an AC tone at the same frequency. Simultaneously with the DPOAEs, vibrations at the teeth were measured with an accelerometer attached using a custom-made holder. It was possible to record DPOAEs for all three stimulation modes. For AC-DC, DPOAEs were not detected above the noise floor below 2 kHz but were detectable at the higher frequencies. The best response was measured at or above 2 kHz with L2 = 60 dB SPL. The acceleration measured at the teeth for stimulation on the dura was lower than that for stimulation on the bone, especially below 3 kHz. We demonstrate a proof-of-concept comparison of DPOAEs and teeth acceleration levels elicited by a bone vibrator placed either against the skin-covered temporal bone, as in audiometry, or directly against the dura mater in patients undergoing a craniotomy. It was demonstrated that DPOAEs could be elicited via non-osseous pathways within the skull contents and that the required measurements could be performed intra-operatively.

23 December 2013 in JMIR Research Protocols
Verified
Journal Article
Open access
RSReto Stump
Reto Stump
SHSilvia Haueis
Silvia Haueis
NKNicola Kalt
Nicola Kalt
CTChristoph Tschuor
Christoph Tschuor
PLPerparim Limani
Perparim Limani
SBStefan Breitenstein
Stefan Breitenstein
Transplantation and Surgical Strategies in Patients With Neuroendocrine Liver Metastases: Protocol of Four Systematic Reviews

23 October 2025 in EP Europace
Verified
Journal Article
Open access
JBJonas Brügger
Jonas Brügger
CICorinne Isenegger
Corinne Isenegger
FJFabian Jordan
Fabian Jordan
BSBehnam Subin
Behnam Subin
RSReto Stump
Reto Stump
PBPatrick Badertscher
Patrick Badertscher
Aims: Pulsed-field ablation (PFA) is a non-thermal energy source for pulmonary vein isolation (PVI), offering advantages in safety and procedural efficiency. However, data comparing anterior mitral isthmus line (MIL) ablation using PFA vs. conventional radiofrequency ablation (RFA) are scarce. This study aimed to compare procedural characteristics, safety, and arrhythmia recurrence following PVI with additional anterior MIL ablation using PFA vs. RFA. Methods and results: In this prospective, single-centre analysis from the SWISS-AF-PVI registry, 129 patients (median age 70 years, 40% female) undergoing PVI with anterior MIL ablation were included. Patients received either PFA with a pentaspline catheter (n = 61) or RFA using a 3.5 mm irrigated tip catheter (n = 68). Procedural parameters, complications, and arrhythmia recurrence were assessed over a median follow-up of 327 days. PFA significantly reduced total procedure time (71 vs. 108 min, P < 0.001), LA dwell time (53 vs. 80 min, P < 0.001), and ablation time (27 vs. 50 min, P < 0.001) compared to RFA. MIL ablation with PFA required fewer applications (14; 35 s vs. 473 s RFA, P < 0.001). Arrhythmia-free survival was similar between groups (PFA 48.8% vs. RFA 61.8%, P = 0.34). Among 34 patients undergoing redo procedures, incomplete MIL was found in 53%, with no significant difference between groups. Three major complications occurred. Conclusion: Anterior MIL ablation using PFA is feasible, safe, and more time-efficient than RFA, with comparable mid-term arrhythmia outcomes. However, high rates of MIL reconnection and arrhythmia recurrence highlights the need to improve lesion durability.

2 September 2026 in EP Europace
Verified
Journal Article
Open access
CICorinne Isenegger
Corinne Isenegger
ABAlexander Breitenstein
Alexander Breitenstein
NSNiklas Stauffer
Niklas Stauffer
PKPascal Koepfli
Pascal Koepfli
DSDavid Siemer
David Siemer
PBPatrick Badertscher
Patrick Badertscher

16 October 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
RSReto Stump
Reto Stump
JBJonas Brügger
Jonas Brügger
PBPatrick Badertscher
Patrick Badertscher
Wearable devices for rhythm monitoring are increasingly available and are being used by patients across a broad spectrum of technologies, including smartwatches with electrocardiogram (ECG)-recording functions and ECG patch systems. Early development of automated rhythm classification algorithms using artificial intelligence primarily focused on atrial fibrillation (AF), although indications and validated use cases differ substantially between device types and continue to evolve. This review aims to provide an overview of contemporary smart devices, their capabilities in arrhythmia care, and future perspectives. Currently, two main technologies are used for rhythm assessment: photoplethysmography (PPG) and single- or multi-lead electrocardiography. PPG enables continuous monitoring of heart rate and pulse regularity, whereas ECG acquisition is typically user-initiated. The use of a 30-second single-lead ECG (SL-ECG) strip with physician confirmation for the diagnosis of AF is supported by current ESC AF guidelines. Systematic screening approaches using wearables have demonstrated higher AF detection rates compared with standard diagnostic pathways; however, whether this translates into improved stroke prevention remains to be proven. Beyond AF, wearables may be particularly useful for infrequent symptomatic arrhythmias, such as supraventricular tachycardias, by enabling SL-ECG recording during symptoms and thereby supporting diagnosis and management. Additional applications include monitoring of QT prolongation, conduction disturbances, and rhythm surveillance following interventions. As an established alternative to user-dependent ECG acquisition, ECG patches provide continuous rhythm recording for up to 30 days and are generally more user-friendly than conventional Holter monitoring. A key challenge remains automated rhythm detection for non-AF arrhythmias, as well as a relevant proportion of inconclusive tracings in real-world populations, for example in the presence of conduction abnormalities or frequent premature atrial or ventricular complexes. From a physician’s perspective, clear workflows and dedicated technical solutions are essential to manage the growing volume of data, and reimbursement mechanisms for analysis of these recordings must be established. Ultimately, the future of wearable-based rhythm monitoring lies in its structured integration into clinical workflows, enabling more individualized and optimized arrhythmia care. In parallel, combining rhythm information with additional health metrics may facilitate a more holistic approach to prevention and management of cardiovascular disease. Despite all technical advances, traditional Holter ECG still has irreplaceable value in patients with frequent arrhythmia symptoms or when coronary vasospasms or Brugada syndrome are suspected.